$XERS News

Xeris Biopharma: A Commercial Stage Pharma That May Be A Slow-Burn Buy Opportunity

Barclays Maintains Overweight on Xeris Biopharma Holdings, Raises Price Target to $12

Xeris Biopharma Holdings, Inc. (XERS) Q2 2026 Earnings Call Transcript

Xeris Biopharma Holdings Q2 EPS $(0.18) Misses $0.00 Estimate, Sales $92.100M Beat $90.225M Estimate

Xeris Biopharma Holdings Raises FY2026 Sales Guidance from $380.000M-$390.000M to $385.000M-$390.000M vs $385.229M Est

Jim Cramer Blesses a Caller’s Speculative Investment in Xeris Biopharma

Xeris Biopharma Announces Notice of Allowance From U.S. Patent and Trademark Office for New Patent Covering KEVEYIS®

Xeris Pharmaceuticals Issued Notice Of Allowance From U.S. Patent And Trademark Office Regarding Its Patent Application Entitled Compositions And Methods Of Use

Xeris Biopharma Announces Private Exchange of Convertible Notes

Xeris Biopharma Enters Separate Exchange Agreements With Certain Holders Of Its 8.00% Convertible Senior Notes Due 2028 To Retire ~$23M Of The Notes For ~$23M In Cash And A Number Of Shares

Shareholders Will Be Pleased With The Quality of Xeris Biopharma Holdings' (NASDAQ:XERS) Earnings

Results: Xeris Biopharma Holdings, Inc. Confounded Analyst Expectations With A Surprise Profit

Xeris Biopharma Q1 Earnings Call Highlights

Xeris Biopharma Holdings, Inc. Q1 2026 Earnings Call Summary

Xeris Biopharma Holdings (XERS) Is Up 8.2% After Swing to Q1 Profitability - What's Changed

Xeris (XERS) Q1 2026 Earnings Call Transcript

Xeris Biopharma Holdings, Inc. (XERS) Q1 2026 Earnings Call Transcript

Xeris Biopharma (XERS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Xeris Biopharma (NASDAQ:XERS) Achieves First Profit, Beats Q1 Estimates with 95% Recorlev Surge

Xeris Biopharma Reports First Quarter 2026 Financial Results